Filana Therapeutics, Inc. (FLNA)

Filana Therapeutics, Inc. is a clinical-stage biotechnology company developing treatments for neurological diseases. Its lead drug candidate is simufilam, an oral small molecule that the company is now developing for epilepsy associated with tuberous sclerosis complex, a rare genetic disorder that often causes difficult-to-control seizures.

Simufilam was previously studied in Alzheimer's disease, and the company has also worked on SavaDx, an early-stage blood-based diagnostic for Alzheimer's. Following its strategic shift, Filana has focused its development work on tuberous sclerosis complex.

The company was formerly known as Cassava Sciences and adopted the Filana Therapeutics name in 2026. It is headquartered in Austin, Texas, and its common stock trades on the Nasdaq Stock Market under the ticker FLNA.